Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra
BUDAPEST, Hungary, Nov. 17 /PRNewswire/ — Hungarian drug producer Biropharma and patent holders of its main product Avemar dispute the connection American BioSciences Inc. and its partner Mate Hidvegi are making between their recently introduced product AveUltra and Avemar, a dietary supplement being used in cancer treatment internationally for 11 years.
“AveUltra and Avemar are two different sets of compounds hence the qualities of Avemar can be attributed exclusively to Avemar, therefore all references of AveUltra to Avemar is scientifically unfounded, deceptive and abundantly unethical,” Avemar’s co-inventors state on Avemar’s website (www.avemar.com).
Avemar is a wheat germ extract formula under patent protection designed to treat cancer patients. It is produced by Biropharma based on a definite-term contract with the holders of its patent. The product is distributed under the brand ‘Ave’ in the U.S.
Hidvegi, one of the patent holders, has teamed up with American BioSciences to start the U.S.-based production of AveUltra, a dietary supplement also based on wheat germ extract, but different from Avemar. According to their claims, AveUltra is developed from Avemar, however, no scientific or otherwise experimental data supports this assertion.
Several clinical studies investigated the various benefits associated with Avemar treatment and the results were published in prestigious peer reviewed medical journals. These publications cannot be used to support the claims of AveUltra.
The producers of AveUltra planned to announce the start of U.S.-based manufacturing of AveUltra at the Society of Integrative Oncology’s 6th International Conference at the New York Academy of Medicine on Nov. 12-13.
Avemar’s Hungarian producer Biropharma, three co-inventors and a patent holder of Avemar are disputing the steps and behavior of American BioSciences Inc. and Mate Hidvegi and planning to take all necessary steps to protect their rights in Hungary and in the United States.
According to Biropharma, the start of U.S. production of a product referring to Avemar is a series of violations of contractual rights that might make the Hungarian company go out of business.
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.